drugset / Trial / NCT05891587

Semaglutide Therapy for Alcohol Reduction - Tulsa

NCT05891587

RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this research study is to determine if semaglutide, when compared to placebo, is safe and may reduce alcohol drinking in individuals who endorse symptoms consistent with alcohol use disorder.

Timeline

Start
2023-07-07
Primary completion
2025-07-30
Completion
2025-10-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Semaglutide Peptide 1 mg Subcutaneous